Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

View Full Paper
Ask AI
Bookmark
Share

Authors

KZKeshu ZhouLZLiqun ZouLWLi Wang

Discussion

Loading...

Member takes

Overview

Observational analysis reveals high remission rates in mantle cell lymphoma patients, suggesting Mesutoclax may benefit those with BTK inhibitor resistance.

Key Points

  • Median progression-free survival was achieved at 8.3 months in patients previously treated with BTK inhibitors.
  • In a phase I study, 74% of mantle cell lymphoma patients were refractory to BTK inhibitors, indicating high treatment need.
  • Overall response rate reached 87.5% with 46.9% complete responses reported across multiple dose levels.
  • Safety profile of Mesutoclax demonstrated low toxicity with almost all treatment-emergent adverse events being grade 1-2.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d964https://doi.org/10.1182/blood-2025-887
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1/2 study2025 · 6 citations
  2. 2Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma2025
  3. 3Real-world treatment and safety outcomes of patients with Mantle Cell Lymphoma in the United States2025
  4. 4Initial treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma in the era of BTK inhibitors: A multicenter real-world study2025
  5. 5The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment2025